Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityFTR / Frontier Communications Corp. (35906A108)
President and CEOMCCARTHY DANIEL J
IndustryTelephone Communications, Except Radiotelephone
Institutional Owners31
Institutional Shares82,025,541 - 102.21%
Institutional Value$ 5,874,360,000 USD
Related 17453BAJ0 / Citizens Communications 9% Senior Notes 8/15/31
17453BAT8 / Citizens Communications Co Senior Notes 6.625% 03/15/15
17453BAW1 / Citizens Communications Co Senior Notes 7.125% 03/15/19
17453BAS0 / Citizens Communications Co Senior Notes 7.875% 01/15/27
177342AP7 / Citizens Utilities 7.05% Debs 10/1/46
177342AL6 / Citizens Utilities 7.45% Debs 7/1/35
177342AM4 / Citizens Utils Co Del Debentures 7% 11/01/25
177342AQ5 / Citizens Utils Co Del Debentures Mbia 7% 11/01/25
35906AAM0 / Frontier Communications 7.125% 01/15/23
35906AAD0 / Frontier Communications 7.875% Senior Notes 04/15/15
35906AAF5 / Frontier Communications 8.25% Senior Notes 04/15/17
35906AAA6 / Frontier Communications 8.25% Senior Notes 05/01/14
35906AAH1 / Frontier Communications 8.50% Senior Notes 04/15/20
FTRPR / Frontier Communications Corp.
35906AAX6 / Frontier Communications Corp. 11% Bond due 2025-9-15
35906AAZ1 / Frontier Communications Corp. 11% European Bond due 2025-9-25
35906AAB4 / Frontier Communications Corp Senior Notes 8.125% 10/01/18

Institutional Stock Ownership and Shareholders()

FTR / Frontier Communications Corp. Institutional Ownership

Frontier Communications Corp. (NASDAQ:FTR) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 82,025,541 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Group LTD, BlackRock Investment Management, LLC, BlackRock Advisors LLC, PVG Asset Management, BlackRock Japan Co. Ltd, Aberdeen Asset Management Plc/uk, R&F Capital Advisors LP, and Thrax Management, LLC.
Frontier Communications Corp. (NASDAQ:FTR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ftr"><img src="https://images.fintel.io/us-ftr-so.png" alt="FTR / Frontier Communications Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Fund Advisors 25,173,459 27,408,865 8.88 104,722 92,642 -11.54
2017-05-15 13F-HR R&F Capital Advisors LP 95,054 501,638 427.74 321 1,074 234.58
2018-05-14 13F-HR Camelot Portfolios, LLC 75,108 0 -100.00 508 0 -100.00
2017-02-14 13F-HR PVG Asset Management 1,656,750 5,599,815
2017-07-10 13F-HR CAPSTONE ASSET MANAGEMENT CO 72,234 44,978 -37.73 155 52 -66.45
2017-05-10 13F-HR Concert Wealth Management Inc. 11,456 0 -100.00 38 0 -100.00
2017-05-01 13F-HR Spot Trading L.L.C 0 4,558 0 10
2017-05-01 13F-HR Spot Trading L.L.C Put 53,100 114
2018-05-10 13F-HR Vantage Investment Advisors, LLC 2,131 2,129 -0.09 14 16 14.29
2018-05-17 13F-HR PVG ASSET MANAGEMENT CORP 119,425 0 -100.00 807,313 0 -100.00
2017-08-08 13F-HR Airain ltd 2,536,962 0 -100.00 5,429 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 32,908,876 33,915,267 3.06 136,901 114,634 -16.27
2017-02-10 13F-HR BlackRock Japan Co. Ltd 1,401,366 1,414,516 0.94 5,830 4,781 -17.99
2017-02-21 13F-HR/A Thrax Management, LLC Put 220,000 744
2018-07-20 13F-HR WHITTIER TRUST CO 0 650 0 4
2017-08-14 13F-HR Fore Research & Management, LP 160,000 105,000 -34.38 342 121 -64.62
2017-08-10 13F-HR ABERDEEN ASSET MANAGEMENT PLC/UK 367,279 706,048 92.24 786 819 4.20
2017-08-18 13F-HR WFG Advisors, LP 50,026 0 -100.00 107 0 -100.00
2016-11-14 13F-HR MASON STREET ADVISORS, LLC 158,690 660
2018-07-17 13F-HR Gemmer Asset Management LLC 8 8 0.00 0 0
2017-04-07 13F-HR CT Financial Advisors LLC 2,500 2,500 0.00 8,450 5,350 -36.69
2018-07-23 13F-HR ORRSTOWN FINANCIAL SERVICES INC 0 480 0 1
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 298,398 0 -100.00 346 0 -100.00
2017-01-23 13F-HR KANALY TRUST CO 259 1
2017-02-10 13F-HR BlackRock Group LTD 11,642,719 11,363,837 -2.40 48,434 38,410 -20.70
2016-11-14 13F-HR Mizuho Asset Management Co.,Ltd. 94,533 94,533 0.00 467 393 -15.85
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 252,546 43,900 -82.62 853 94 -88.98
2017-07-27 13F-HR Spot Trading L.l.c. Put 64,600 75
2018-07-17 13F-HR Nelson Roberts Investment Advisors, LLC 0 8 0 0
2017-04-17 13F-HR Pinnacle Bank 491 1
2018-04-23 13F-HR Sterling Investment Advisors, Ltd. 8 8 0.00 0 0
2017-05-08 13F-HR ARXIS SECURITIES LLC 11,860 0 -100.00 40 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 2,642,910 2,725,197 3.11 10,995 9,211 -16.23
2017-07-27 13F-HR Spot Trading L.l.c. 26,453 31
2017-07-28 13F-HR RONALD BLUE & CO LLC 17,756 0 -100.00 38 0 -100.00
2017-02-28 13F-HR HIGH POINT BANK & TRUST CO 1,006 1,006 0.00 4 4 0.00
2017-01-13 13F-HR MetLife Securities, Inc 134,496 117,137 -12.91 559 396 -29.16
2017-05-16 13F-HR FIRST FINANCIAL EQUITY CORPORATION 10,110 20
2017-05-01 13F-HR Spot Trading L.L.C Call 28,000 60
2018-05-11 13F-HR UNITED FIRE GROUP INC 859 658 -23.40 6 5 -16.67
2017-02-10 13F-HR BlackRock Advisors LLC 1,539,589 1,719,663 11.70 6,405 5,813 -9.24
2018-05-01 13F-HR Alpha Omega Wealth Management LLC 20 0 -100.00 0 0
2017-07-27 13F-HR Spot Trading L.l.c. Call 17,000 20
2018-05-07 13F-HR Focused Wealth Management, Inc 216 204 -5.56 1 2 100.00
FTR: Frontier Communications Analysis and Research Report

2018-03-04 - Asif

Business Frontier Communications Corporation (Frontier) is a provider of communications services in the United States, with approximately 4.9 million customers, 3.9 million broadband subscribers and 22,700 employees, operating in 29 states. In recent years, Frontier has completed multiple acquisitions. On April 1, 2016, the company acquired the wireline operations of Verizon Communications, Inc. in California, Texas and Florida for a purchase price of $10,540 million in cash and assumed debt. The company conduct business with both consumer and commercial customers. Consumer. The company provide broadband, video, voice and other services and products to its consumer customers. The company deliver these services generally over a combination of fiber and copper-based networks. Commercial (small, medium and large enterprise business (SME) as well as wholesale customers). Com...

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

New Strong Buy Stocks for July 23rd

1h zacks
Comstock Resources, Inc. (CRK - Free Report) : This independent energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 17.1% over the last 60 days. (15-1)

Preferred Stocks And Baby Bonds: Redeemed Issues

2018-07-22 seekingalpha
There is no incredible value created by the series of articles covering fixed income products whose Call Option was finally, or perhaps timely, exercised by the issuing company. However, it turns out that not all of us have the resources and time to keep track of their portfolio, thus we are continuing our coverage of these events. (8-0)

Abbott (ABT) Beats on Earnings and Revenues in Q2

2018-07-18 zacks
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. (24-0)

Grupo Simec (SIM) Catches Eye: Stock Jumps 7.1%

2018-07-18 zacks
Grupo Simec, S.A.B. de C.V. (SIM - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 17.1% in the past one-month time frame. (17-0)

Should You Buy E*TRADE (ETFC) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (18-0)

CUSIP: 35906A108